The class I ATP competitive inhibitors vemurafenib and dabra...

created [InstanceEdit:6802239] Rothfels, Karen, 2015-10-02
dbId 6802240
displayName The class I ATP competitive inhibitors vemurafenib and dabra...
schemaClass Summation
text The class I ATP competitive inhibitors vemurafenib and dabrafenib have been approved for treatment of V600E melanoma, and other BRAF-selective inhibitors are in clinical and preclinical trials. These inhibitors bind to the active conformation of the enzyme promoted by the V600E mutation (King et al, 2006; Tsai et al, 2008).
Cite Us!